Your browser doesn't support javascript.
loading
Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency Virus.
Schnittman, Samuel R; Kolossváry, Márton; Beck-Engeser, Gabriele; Fitch, Kathleen V; Ambayec, Gabrielle C; Nance, Robin M; Zanni, Markella V; Diggs, Marissa; Chan, Fay; McCallum, Sara; Toribio, Mabel; Bamford, Laura; Fichtenbaum, Carl J; Eron, Joseph J; Jacobson, Jeffrey M; Mayer, Kenneth H; Malvestutto, Carlos; Bloomfield, Gerald S; Moore, Richard D; Umbleja, Triin; Saag, Michael S; Aberg, Judith A; Currier, Judith S; Delaney, Joseph A C; Martin, Jeffrey N; Lu, Michael T; Douglas, Pamela S; Ribaudo, Heather J; Crane, Heidi M; Hunt, Peter W; Grinspoon, Steven K.
Affiliation
  • Schnittman SR; Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Kolossváry M; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Beck-Engeser G; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Fitch KV; Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.
  • Ambayec GC; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Nance RM; Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.
  • Zanni MV; Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Diggs M; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Chan F; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • McCallum S; Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.
  • Toribio M; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Bamford L; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Fichtenbaum CJ; Division of Infectious Diseases and Global Public Health, University of California, San Diego, San Diego, California, USA.
  • Eron JJ; Division of Infectious Diseases, University of Cincinnati, Cincinnati, Ohio, USA.
  • Jacobson JM; Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Mayer KH; Division of Infectious Diseases, Case Western Reserve University, Cleveland, Ohio, USA.
  • Malvestutto C; Fenway Health and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
  • Bloomfield GS; Division of Infectious Diseases, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Moore RD; Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
  • Umbleja T; Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Saag MS; Harvard T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.
  • Aberg JA; Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Currier JS; Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Delaney JAC; Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, California, USA.
  • Martin JN; Department of Epidemiology, University of Washington, Seattle, Washington, USA.
  • Lu MT; College of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Douglas PS; Department of Epidemiology and Biostatistics, University of California, San Francisco School of Medicine, San Francisco, California, USA.
  • Ribaudo HJ; Cardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Crane HM; Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Hunt PW; Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Grinspoon SK; Department of Medicine, University of Washington, Seattle, Washington, USA.
Open Forum Infect Dis ; 10(10): ofad467, 2023 Oct.
Article in En | MEDLINE | ID: mdl-37869406
ABSTRACT
Plasma vascular endothelial growth factor (VEGF) coreceptor neuropilin-1 (NRP-1) had the largest association with coronary plaque in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) proteomics analysis. With little known about NRP-1 in people with human immunodeficiency virus (PWH), we explored its relation to other proteins in REPRIEVE and validated our findings through a Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) case-cohort study by assessing its relation to host factors and incident cardiovascular disease and cancer. Within REPRIEVE, NRP-1 was associated with proteins involved in angiogenesis, signal transduction, immunoregulation, and cell migration/adhesion. Within CNICS, NRP-1 was associated with key host factors, including older age and male sex. NRP-1 was associated with an increased hazard of multiple cancers but a decreased prostate cancer risk. Finally, NRP-1 was most strongly associated with mortality and type 2 myocardial infarction. These data suggest that NRP-1 is part of a clinically relevant immunoregulatory pathway related to multiple comorbidities in PWH. Clinical Trials Registration. NCT02344290.
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Open Forum Infect Dis Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Open Forum Infect Dis Year: 2023 Document type: Article